Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from NovoCure ( (NVCR) ) is now available.
On September 15, 2025, Novocure announced that Japan’s Ministry of Health, Labour and Welfare approved Optune Lua® for use with PD-1/PD-L1 inhibitors in treating unresectable advanced/recurrent non-small cell lung cancer (NSCLC) after platinum-based chemotherapy. This approval, supported by the Phase 3 LUNAR trial, marks a significant advancement for patients, showing improved survival rates without severe side effects. The approval enhances Novocure’s market positioning in Japan, addressing the urgent need for innovative NSCLC treatments, and potentially benefiting stakeholders by providing a new therapeutic option.
The most recent analyst rating on (NVCR) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on NovoCure stock, see the NVCR Stock Forecast page.
Spark’s Take on NVCR Stock
According to Spark, TipRanks’ AI Analyst, NVCR is a Neutral.
NovoCure’s overall stock score is primarily influenced by its financial performance challenges, including persistent losses and high leverage. Technical analysis indicates a bearish trend, and valuation metrics are poor due to negative earnings. The earnings call provided some positive insights into clinical trials and market expansion, slightly offsetting the negative aspects.
To see Spark’s full report on NVCR stock, click here.
More about NovoCure
Novocure is a global oncology company focused on extending survival in aggressive cancers through its innovative Tumor Treating Fields (TTFields) therapy. The company’s products are approved for treating glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma, and pleural mesothelioma, with ongoing clinical trials exploring further applications. Novocure is headquartered in Baar, Switzerland, with U.S. headquarters in Portsmouth, New Hampshire, and R&D facilities in Haifa, Israel.
Average Trading Volume: 1,593,406
Technical Sentiment Signal: Sell
Current Market Cap: $1.36B
See more data about NVCR stock on TipRanks’ Stock Analysis page.